Immune function testing of human pharmaceuticals: regulatory overshoot?

Author： van der Laan Jan Willem van Loveren Henk

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.4, Iss.1, 2005-01, pp. : 1-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Carcinogenicity Testing and the Evaluation of Regulatory Requirements for Pharmaceuticals

By Contrera J.F. Jacobs A.C. deGeorge J.J.

Regulatory Toxicology and Pharmacology, Vol. 25, Iss. 2, 1997-04 ,pp. : 130-145

Academic Press

Access to resources Recommend Favorite

Pharmaceuticals in the Environment—A Human Risk?

By Christensen F.M.

Regulatory Toxicology and Pharmacology, Vol. 28, Iss. 3, 1998-12 ,pp. : 212-221

Academic Press

Access to resources Recommend Favorite

Post-Approval Changes in Pharmaceuticals: Regulatory Perspectives in Europe

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 2, Iss. 2, 2015-08 ,pp. : 60-68

Bentham Science Publishers

Access to resources Recommend Favorite

Current regulatory approaches of bioequivalence testing

By Karalis Vangelis Macheras Panos

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 8, 2012-08 ,pp. : 929-942

Informa Healthcare

Access to resources Recommend Favorite

Storage Conditions for Stability Testing of Pharmaceuticals in Hot and Humid Regions

By Bott Rubiana F. Oliveira Wanderley P.

Drug Development and Industrial Pharmacy, Vol. 33, Iss. 4, 2007-04 ,pp. : 393-401

Informa Healthcare

Access to resources Recommend Favorite